Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281462 · ClinicalTrials.gov registry record · Phase 2
Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT01281462 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 217 participants.
The verdict
NCT01281462, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
This is a study in adult subjects with complicated urinary tract infection (cUTI) comparing treatment with intravenous (IV) coadministered ceftaroline fosamil and NXL104 versus treatment with IV doripenem.
Interventions
- DRUG Placebo
- DRUG Doripenem
- DRUG Ceftaroline fosamil and NXL104 (q8h)
- DRUG Ceftaroline fosamil and NXL104 (q12h)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281462
The ClinicalTrials.gov registry entry for NCT01281462 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01281462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281462 about?
NCT01281462 is a clinical study titled "Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections". This is a study in adult subjects with complicated urinary tract infection (cUTI) comparing treatment with intravenous (IV) coadministered ceftaroline fosamil and NXL104 versus treatment with IV doripenem.
What is the current status of trial NCT01281462?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2010-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01281462?
The interventions under investigation include: Placebo (DRUG), Doripenem (DRUG), Ceftaroline fosamil and NXL104 (q8h) (DRUG), Ceftaroline fosamil and NXL104 (q12h) (DRUG).
Who is sponsoring clinical trial NCT01281462?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.